NasdaqGS:MRVI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Maravai LifeSciences Holdings, Inc. operates as a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. More Details

Rewards

Earnings are forecast to grow 22.07% per year

Revenue grew by 15.6% over the past year

Risk Analysis

No risks detected for MRVI from our risk checks.


Snowflake Analysis

High growth potential with worrying balance sheet.


Similar Companies

Share Price & News

How has Maravai LifeSciences Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MRVI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: Insufficient data to determine MRVI's volatility change over the past year.


Market Performance


7 Day Return

5.6%

MRVI

0.3%

US Life Sciences

-1.0%

US Market


1 Year Return

n/a

MRVI

45.7%

US Life Sciences

19.6%

US Market

Return vs Industry: Insufficient data to determine how MRVI performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how MRVI performed against the US Market.


Shareholder returns

MRVIIndustryMarket
7 Day5.6%0.3%-1.0%
30 Day-6.0%7.7%2.2%
90 Dayn/a14.5%11.5%
1 Yearn/a46.0%45.7%22.3%19.6%
3 Yearn/a110.1%108.8%45.3%35.7%
5 Yearn/a227.2%223.2%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is Maravai LifeSciences Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Maravai LifeSciences Holdings undervalued compared to its fair value and its price relative to the market?


Share Price vs. Fair Value

Below Fair Value: MRVI ($27.77) is trading above our estimate of fair value ($17.74)

Significantly Below Fair Value: MRVI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: Insufficient data to calculate MRVI's PE Ratio to determine if it is good value compared to the US Life Sciences industry average.

PE vs Market: Insufficient data to calculate MRVI's PE Ratio to determine if it is good value compared to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MRVI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: Insufficient data to calculate MRVI's PB Ratio to determine if it is good value.


Next Steps

Future Growth

How is Maravai LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

22.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRVI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: MRVI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MRVI's is expected to become profitable in the next 3 years.

Revenue vs Market: MRVI's revenue (16.1% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: MRVI's revenue (16.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MRVI's Return on Equity is forecast to be very high in 3 years time (45.8%).


Next Steps

Past Performance

How has Maravai LifeSciences Holdings performed over the past 5 years?

0.04%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: MRVI is currently unprofitable.

Growing Profit Margin: MRVI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if MRVI's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare MRVI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRVI is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (30.4%).


Return on Equity

High ROE: MRVI has a negative Return on Equity (-3.6%), as it is currently unprofitable.


Next Steps

Financial Health

How is Maravai LifeSciences Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: MRVI's short term assets ($60.6M) exceed its short term liabilities ($29.6M).

Long Term Liabilities: MRVI's short term assets ($60.6M) do not cover its long term liabilities ($403.6M).


Debt to Equity History and Analysis

Debt Level: MRVI's debt to equity ratio (233.2%) is considered high.

Reducing Debt: Insufficient data to determine if MRVI's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: MRVI's debt is not well covered by operating cash flow (7.1%).

Interest Coverage: MRVI is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Maravai LifeSciences Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MRVI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRVI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MRVI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRVI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MRVI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Carl Hull (61 yo)

6.83yrs

Tenure

Mr. Carl W. Hull serves as a Director at Ortho Clinical Diagnostics Holdings plc. Mr. Hull is Partner, Co-Founder, Chief Executive Officer and Chairman of the Board at Maravai LifeSciences Holdings, Inc. H...


Leadership Team

NamePositionTenureCompensationOwnership
Carl Hull
Partner6.83yrsno data0.035%
$ 2.7m
Eric Tardif
Partner6.83yrsno datano data
Kevin Herde
VP & CFO3.67yrsno datano data
Kurt Oreshack
General Counsel0.17yrno data0.0075%
$ 574.3k
Christine Dolan
Chief Operating Officer of Biologics Safety Testing3.25yrsno datano data
Brian Neel
Chief Operating Officer of Nucleic Acid Production3.25yrsno datano data
Lisa Sellers
Chief Operating Officer of Protein Detection0.42yrno data0.019%
$ 1.4m

3.3yrs

Average Tenure

48yo

Average Age

Experienced Management: MRVI's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Carl Hull
Partner6.83yrsno data0.035%
$ 2.7m
Constantine Mihas
Independent Director0.17yrno datano data
Sean Cunningham
Director0.17yrno datano data
Gregory Lucier
Independent Director0.17yrno data0.027%
$ 2.1m
Susannah Gray
Independent Director0.17yrno data0.032%
$ 2.4m
Benjamin Daverman
Independent Director0.17yrno datano data
Robert Hance
Independent Director0.17yrno data0.022%
$ 1.7m
Luke Marker
Director0.17yrno datano data
Murali Prahalad
Independent Director0.17yrno data0.030%
$ 2.3m
Jessica Hopfield
Independent Director0.17yrno data0.062%
$ 4.7m
Anat Ashkenazi
Independent Director0.17yrno datano data

0.2yrs

Average Tenure

55yo

Average Age

Experienced Board: MRVI's board of directors are not considered experienced ( 0.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MRVI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: MRVI only recently listed within the past 12 months.


Top Shareholders

Company Information

Maravai LifeSciences Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Maravai LifeSciences Holdings, Inc.
  • Ticker: MRVI
  • Exchange: NasdaqGS
  • Founded: 2020
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$7.688b
  • Market Cap: US$2.788b
  • Shares outstanding: 276.84m
  • Website: https://www.maravai.com

Location

  • Maravai LifeSciences Holdings, Inc.
  • 10770 Wateridge Circle
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRVINasdaqGS (Nasdaq Global Select)YesClass A Common StockUSUSDNov 2020

Biography

Maravai LifeSciences Holdings, Inc. operates as a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseas...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/17 00:00
End of Day Share Price2021/01/15 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.